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Complex multimorbidity and health outcomes in older adult cancer 
survivorsa
David F. Warner1, Nicholas K. Schiltz2, Kurt C. Stange3,6, Charles W. Given4, Cynthia 
Owusu5,6, Nathan A. Berger5,6, Siran M. Koroukian2,6
Abstract
Objective: To characterize complex multimorbidity among cancer survivors and evaluate the 
association between cancer survivorship, time since cancer diagnosis, and self-reported fair/poor 
health, self-rated worse health in 2 years, and 2-year mortality.
Methods: We used the 2010–2012 Health and Retirement Study. Cancer survivors were indi-
viduals who reported a (nonskin) cancer diagnosis 2 years or more before the interview. We defined 
complex multimorbidity as the co-occurrence of chronic conditions, functional limitations, and/or 
geriatric syndromes. In addition to descriptive analyses, we used logistic regression to evaluate the 
independent association between cancer survivor status and health outcomes. We also examined 
whether cancer survivorship differed by the number of years since diagnosis.
Results: Among 15,808 older adults (age ≥50 years), 11.8% were cancer survivors. Compared 
with cancer-free individuals, a greater percentage of cancer survivors had complex multimorbidity: 
co-occurring chronic conditions, functional limitations, and geriatric syndromes. Cancer survivor-
ship was significantly associated with self-reported fair/poor health, self-rated worse health in 2 
years, and 2-year mortality. These effects declined with the number of years since diagnosis for fair/
poor health and mortality but not for self-rated worse health.
Conclusion: Cancer survivor status is independently associated with more complex multi-
morbidity, and with worse health outcomes. These effects attenuate with time, except for patient 
perception of being in worse health.
Keywords: Comorbidity; functional limitations; geriatric syndromes; multimorbidity; health 
status; health decline; mortality, cancer survivorship
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Introduction
Cancer survivors constitute a growing segment 
of the population, reflecting, in great part, an 
aging population and the associated increase in 
the number new cancer cases combined with 
improvements in cancer treatment and survival. 
A recent study estimated that in 2016 there were 
15.5 million cancer survivors in the United 
States, a number projected to grow to more than 
20 million by January 2026 [1]. Overall, 56% 
of cancer survivors had received a diagnosis 
of cancer within the previous 10 years, and 
74% were aged 60 years or older [1].
Previous studies have reported great clini-
cal heterogeneity [2] and a higher chronic 
condition comorbidity burden among cancer 
survivors than among their cancer-free coun-
terparts [3] – what Leach et al. [4] described 
Multimorbidity and health outcomes in older adults
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as a “complex health profile.” Many of the comorbidities 
acquired after cancer may be associated with chemotoxicity 
[5–7], and effects of hormonal treatment [8–10] or radiation 
treatment [11–14]. In addition to chronic medical conditions, 
poor mental-health-related quality of life is more prevalent 
among cancer survivors than among cancer-free adults [15], 
and clinically meaningful levels of depression and anxi-
ety have been reported across subgroups of cancer survivors 
[16–18].
A conference held jointly by the Cancer and Aging 
Research Group, the National Cancer Institute, and the 
National Institute on Aging provided a “framework for 
future research to improve the evidence base for the clini-
cal care of older adults with cancer” [19]. In it, the group 
identified the first knowledge gap to be the lack of geriatric 
assessment-guided interventions to improve outcomes for 
older patients with cancer. Another report from a survey 
by the American Society of Clinical Oncology highlighted 
“relative lack of research” involving older cancer survivors 
(current age >65 years) [20]. To fill these gaps, however, a 
more comprehensive assessment is needed to evaluate not 
only the chronic condition comorbidity burden among older 
cancer survivors but also their complex multimorbidity bur-
den to account for difficulty with physical functioning and 
geriatric syndromes, in addition to their chronic conditions. 
Such a comprehensive approach in studying the health pro-
file of older cancer survivors is all the more important given 
the role of cancer in further functional decline and increased 
risk of depression [21].
In this study, we use data from the Health and Retirement 
Study (HRS), a longitudinal panel launched in 1992, through 
which a rich array of data are collected biennially on a US 
representative sample of adults aged 50 years or older. We take 
advantage of the rich HRS data to define complex multimor-
bidity as the occurrence or co-occurrence of chronic condi-
tions, functional limitations, and/or geriatric syndromes (e.g., 
poor cognitive functioning, and incontinence). With this more 
expansive definition of multimorbidity, we move away from 
prior studies’ sole reliance on multiple chronic conditions. In 
addition, we acknowledge the cascading effects of chronic 
conditions that manifest themselves in the emergence or wors-
ening of functional limitations and geriatric syndromes, as 
well as the previously documented cumulative effect of these 
conditions relative to health outcomes, including self-reported 
fair/poor health, self-reported worse heath in 2 years, and 
2-year mortality [22].
This study has two objectives: (1) to characterize cancer 
survivors’ complex multimorbidity profile; and (2) to evalu-
ate the independent association between cancer survivor sta-
tus and short-term poor health outcomes, including fair/poor 
self-reported health, self-rated worse health in 2 years, and 
2-year mortality. We hypothesize that after adjustment for the 
multimorbidity profile and potential confounders, cancer sur-
vivor status remains associated with worse health outcomes. 
Furthermore, we hypothesize that the association between 
cancer survivor status and health outcomes is attenuated as 
more time has elapsed since cancer was first diagnosed.
Methods
Overview
This is a short-term study using 2010–2012 data from the 
HRS to compare complex multimorbidity and health out-
comes between cancer survivors and cancer-free individuals. 
Since the data originate from the public use files of the HRS, 
this study was deemed exempt by the Case Western Reserve 
University Institutional Review Board.
Data source
We used 2010–2012 data from the public use files of the HRS. 
The HRS is the largest longitudinal survey study in the United 
States, with data on nearly 30,000 US adults aged 50 years or 
older. Every 2 years, HRS participants are asked to report on 
chronic conditions, functional status, cognitive status, depres-
sive symptoms, and a range of behavioral variables.
Study population
All HRS participants were eligible to be included in the study. 
Respondents with a new (incident) cancer diagnosis in 2010, as 
defined below, were excluded from the study. Respondents had 
to be self-reporting in 2010, and any proxy respondents were 
excluded. Our study population included 15,808 individuals 
(2025 cancer survivors, and 13,783 cancer-free individuals). 
The average time elapsed since diagnosis for cancer survivors 
was slightly more than 12 years.
Warner et al.
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Variables of interest
Outcome variables: The following were our outcome vari-
ables:
•	 Self-reported fair or poor health status in 2010 (versus 
excellent, very good, or good)
•	 Self-rated 2-year decline, coded as ‘1’ if the participant 
rates his/her health as “worse” (versus “better” or “about 
the same”) in 2012 compared with when he or she was 
interviewed in 2010
•	 Two-year mortality, based on deceased status in 2012, 
as reported by the spouse or another relative or through 
probabilistic matching with the National Death Index
Independent variables: Our main independent variable 
was cancer survivor status, coded as ‘1’ if the respondent 
 reported a (nonskin) cancer diagnosis at least 2 years before 
the interview. Otherwise participants were defined as cancer-
free individuals. We coded the time elapsed since cancer diag-
nosis as 2–4 years, 5–9 years, and 10 years or more; alternative 
coding, including a linear specification, yielded similar results. 
Respondents who reported a new cancer diagnosis within the 
prior 2 years were excluded.
Complex multimorbidity was characterized by the presence 
and co-occurrence of chronic conditions, functional limita-
tions, and/or geriatric syndromes in 2010, consistent with our 
previous work [22]. Self-reported chronic conditions included 
hypertension, arthritis, heart disease, lung disease, diabetes, 
stroke, and psychiatric disorders. These conditions were con-
sidered present if the respondent replied in the affirmative to 
the question: “Has the doctor ever told you that you have” one 
of the above conditions?
Functional limitations included self-reported “any dif-
ficulty” in upper body mobility (e.g., reaching or extending 
arms above shoulder level); lower body mobility (e.g., walking 
several blocks or difficulty climbing stairs); strength (e.g., lift-
ing 10 lb); activities of daily living (e.g., eating, dressing, bath-
ing); and instrumental activities of daily living (e.g., preparing 
meals or managing oral medications).
Geriatric syndromes included poor cognitive per-
formance (rated in the bottom tertile on the Telephone 
Interview for Cognitive Status); depression (at least four 
depressive symptoms on the Center for Epidemiological 
Studies Depression Scale; incontinence; visual impairment; 
hearing impairment; persistent dizziness, and severe pain. For 
individuals aged 65 years or older, we also accounted for falls 
as part of geriatric syndromes; respondents younger than 65 
years were not asked about falls.
On the basis of our previous work [22, 23] showing that the 
co-occurrence of chronic conditions, functional limitations, 
and geriatric syndromes had a cumulative effect on health 
outcomes, we derived a composite measure for complex mul-
timorbidity, defined as follows: MM0 in the absence of any 
of the aforementioned conditions; MM1 in the presence (but 
without the co-occurrence) of chronic conditions, functional 
limitations, or geriatric syndromes; MM2 when conditions 
across two of the domains of chronic conditions, functional 
limitations, and geriatric syndromes co-occur; and MM3 
when conditions across all three of these domains co-occur. 
This composite measure has been shown to be associated with 
the outcomes of interest in a dose–response fashion.
Other independent variables include age (grouped in 5-year 
increments), race/ethnicity (white non-Hispanic, black non-
Hispanic, Hispanic, and other), sex (male and female), mari-
tal status (married, divorced, widowed, and never married), 
number of years of education (<9, 9–11, 12, 13–15, 16, and 
≥17), and income as a percentage of the federal poverty level 
(<100%, 100%–199%, 200%–299%, ≥300%). Behavioral 
variables include smoking status (never smoked, former 
smoker, and current smoker), vigorous exercise (“sports or 
activities that are vigorous” at least once per week), alcohol 
use based on average number of drinks per day (none; moder-
ate, one or two drinks; heavy, three or more drinks), and body 
mass index, defined as weight in kilograms divided by the 
square of height in meters (underweight, ≤18 kg/m2; normal/
overweight, 18–29 kg/m2; obese, ≥30 kg/m2).
Analytic strategy
In addition to descriptive analysis, we conducted multivari-
able logistic regression analysis to analyze the independent 
association between cancer survivorship and health outcomes, 
after adjustment for multimorbidity and other potential con-
founders. We estimated two sets of multivariable models. The 
first examined the association between cancer survivor status 
Multimorbidity and health outcomes in older adults
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and the health outcomes; the second examined the associa-
tion between the time since cancer diagnosis and the health 
outcomes. Cancer-free individuals were the reference in both 
sets of models.
We applied survey weights to account for the complex sur-
vey design of the HRS. SAS® version 9.4 was used in all of our 
analyses.
Results
The distribution of the study population by sociodemographic 
variables is presented in Table 1. Cancer survivors accounted 
for 12.81% of participants. A greater percentage of cancer sur-
vivors than cancer-free individuals were aged 70 years or older 
(60.79% vs. 34.64%) and white non-Hispanic (76.69% vs. 
63.56%); P<0.001 for both comparisons. No marked differ-
ences were observed by marital status, education, or income. 
Importantly, however, compared with cancer-free individuals, 
a significantly greater percentage of cancer survivors were 
former smokers (48.20% vs. 39.96%), and fewer engaged in 
vigorous exercise (20.74% vs. 25.59%).
Table 2 presents the percentage of individuals present-
ing with the various chronic conditions, functional limita-
tions, and geriatric syndromes by cancer survivor status. 
Regardless of the condition, the percentage of individu-
als presenting with the condition was significantly higher 
among cancer survivors than among cancer-free individuals. 
However, the greatest differentials between the two groups 
were for arthritis (67.65% vs. 52.98%) and heart disease 
(35.46% vs. 23.20%). Similarly, a greater percentage of can-
cer survivors than their cancer-free counterparts reported 
strength limitations, upper body mobility limitations, lower 
body mobility limitations, and limitations in independent 
activities of daily living. The differential between the two 
groups was the smallest for limitations in activities of daily 
living (4.59% vs. 3.58%, P=0.03; P<0.001 for all other com-
parisons). With regard to geriatric syndromes, we observed 
statistically significant differences between cancer survivors 
and cancer-free individuals with respect to incontinence 
(32.74% vs. 20.76%), severe pain (8.59% vs. 6.38%), hearing 
impairment (24.59% vs. 18.56%), and poor cognitive func-
tioning (33.30% vs. 31.10%, P=0.047; all other comparisons 
significant at P<0.01).
Table 3 shows the distribution of the study population by the 
complex multimorbidity composite score, as well as health out-
comes, by cancer survivor status. Not surprisingly, compared 
with cancer-free individuals, a significantly greater percent-
age of cancer survivors presented with co-occurring chronic 
conditions, functional limitations, and geriatric syndromes, 
or MM3 (34.02% vs. 25.12%), reported fair/poor health sta-
tus (34.79% vs. 25.55%), and rated their health as “worse” 
than that 2 years previously (29.34% vs. 21.42%, P<0.001 for 
all comparisons). Two-year mortality was more than double 
among cancer survivors compared with among cancer-free 
individuals (7.60% and 3.26% respectively, P<0.001).
The findings from our multivariable logistic regression 
analysis showed that the differences in health outcomes 
by cancer survivor status persisted after adjustment for 
age and complex multimorbidity status. Thus, as shown in 
Fig. 1, cancer survivors were significantly likelier to report 
fair/poor health [adjusted odds ratio 1.73, 95% confidence 
interval (CI) 1.49–2.01] or 2-year self-rated worse health 
(adjusted odds ratio 1.32, 95% CI 1.15–1.51), or to die within 
2 years (adjusted odds ratio 1.51, 95% CI 1.16–1.96). Despite 
the higher levels of multimorbidity among cancer survivors, 
preliminary analyses (not shown) did not detect a statisti-
cally significant interaction between cancer survivorship 
and multimorbidity for any of the outcomes. Thus, the effect 
of multimorbidity on the health outcomes was not stronger 
(or weaker) for cancer survivors compared with cancer-free 
individuals.
The analyses examining the effect of time since diagnosis 
showed that the increased likelihood of self-reported fair/poor 
health and 2-year mortality was generally lower the more time 
that had elapsed (Fig. 2). Cancer survivors 10 years or more 
after diagnosis had odds of death that did not differ from that 
of cancer-free individuals. Cancer survivors 5–9 years and 10 
years or more after diagnosis did not differ from one another 
in self-reported fair/poor health but remained different from 
cancer-free individuals. There were no differences in the per-
ception of being in worse health by the time since diagnosis. 
Combined with the results from Fig. 1, this indicates that 
cancer survivors were slightly more likely to rate their health 
worse than that 2 years previously regardless of the time since 
diagnosis.
Warner et al.
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Table 1. Sociodemographic characteristics and health outcomes among cancer survivors and cancer-free individuals
Variables of interest Cancer survivors Cancer-free individuals Total
Age category
 50–54 138 (6.81%) 2550 (18.50%) 2688 (17.00%)
 55–59 180 (8.89%) 2800 (20.31%) 2980 (18.85%)
 60–64 227 (11.21%) 2025 (14.69%) 2252 (14.25%)
 65–69 249 (12.30%) 1635 (11.86%) 1884 (11.92%)
 70–74 385 (19.01%) 1951 (14.16%) 2336 (14.77%)
 75–79 359 (17.73%) 1346 (9.77%) 1705 (10.79%)
 80–84 275 (13.58%) 817 (5.93%) 1092 (6.91%)
 ≥85 212 (10.47%) 659 (4.78%) 871 (5.51%) 
Sexa
 Male 863 (42.62%) 5751 (41.73%) 6614 (41.84%)
 Female 1162 (57.38%) 8032 (58.27%) 9194 (58.16%)
Race/ethnicity
 White non-Hispanic 1553 (76.69%) 8761 (63.56%) 10314 (65.25%)
 Black non-Hispanic 286 (14.12%) 2762 (20.04%) 3048 (19.28%) 
 Hispanic 148 (7.31%) 1828 (13.26%) 1976 (12.50%)
 Other 38 (1.88%) 432 (3.13%) 470 (2.97%)
Marital status
 Married 1213 (59.90%) 8521 (61.82%) 9734 (61.58%)
 Divorced 288 (14.22%) 2785 (15.85%) 2473 (15.64%)
 Widowed 437 (21.58%) 2209 (16.03%) 2646 (16.74%) 
 Never married 87 (4.30%) 868 (6.30%) 955 (6.04%) 
Education (years)b
 <9 159 (7.85%) 1216 (8.82%) 1375 (8.70%) 
 9–11 240 (11.85%) 1564 (11.35%) 1804 (11.41%)
 12 674 (33.28%) 4392 (31.87%) 5066 (32.05%)
 13–15 456 (22.52%) 3361 (24.38%) 3817 (24.15%)
 16 246 (12.15%) 1683 (12.21%) 1929 (12.20%)
 ≥17 250 (12.35%) 1567 (11.37%) 1817 (11.49%)
Income as percentage of federal poverty levelc
 <100% 199 (9.83%) 1716 (12.45%) 1915 (12.11%) 
 100%–199% 417 (20.59%) 2633 (19.11%) 3050 (19.29%) 
 200%–299% 373 (18.42%) 2269 (16.46%) 2642 (16.72%)
 ≥300% 1036 (51.16%) 7165 (51.98%) 8201 (51.88%)
Smoking statusb
 Never smoked 829 (40.94%) 6106 (44.30%) 6935 (43.87%) 
 Former smoker 976 (48.20%) 5508 (39.96%) 6484 (41.02%) 
 Current smoker 220 (10.86%) 2169 (15.74%) 2389 (15.11%)
Alcohol use
 None 1298 (64.10%) 8531 (61.90%) 9829 (62.18%) 
 Moderate 609 (30.07%) 3857 (27.98%) 4466 (28.25%)
 Heavy 118 (5.83%) 1395 (10.12%) 1513 (9.57%)
Multimorbidity and health outcomes in older adults
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Variables of interest Cancer survivors Cancer-free individuals Total
Body mass index (kg/m2)c
 Missing 18 (0.89%) 259 (1.88%) 277 (1.75%)
 Underweight 35 (1.73%) 134 (0.97%) 169 (1.07%)
 Normal/overweight 1322 (65.28%) 8539 (61.95%) 9862 (62.38%)
 Obese 650 (32.10%) 4851 (35.20%) 5501 (34.80%) 
Vigorous exercisec
 No 1605 (79.26%) 10,256 (74.41%) 11,861 (75.03%)
 Yes 420 (20.74%) 3527 (25.59%) 3947 (24.97%)
Total 2025 (100.00%) 13,783 (100.00%) 15,808 (100.00%)
Unless indicated otherwise, (unadjusted) comparisons were significant at P<0.0001.
aP>0.05.
b0.05≤P<0.01.
c0.01≤P<0.001.
Table 1 (continued)
Table 2. Conditions constituting multimorbidity, by cancer survivor status
Conditions of interest Cancer survivors Cancer-free individuals Total
Chronic conditions
 Hypertension 1369 (67.60%) 8204 (59.52%) 9573 (60.56%) 
 Arthritis 1370 (67.65%) 7302 (52.98%) 8672 (54.86%)
 Heart disease 718 (35.46%) 3197 (23.20%) 3915 (24.77%)
 Lung disease 280 (13.83%) 1216 (8.82%) 1496 (9.46%)
 Stroke 253 (12.49%) 1102 (8.00%) 1355 (8.57%)
 Diabetes 553 (27.31%) 3116 (22.61%) 3669 (23.21%)
 Psychiatric conditions 396 (19.56%) 2197 (15.94%) 2593 (16.40%)
Functional limitations
 Strength limitations 1302 (64.30%) 7443 (54.00%) 8745 (55.32%)
 Upper body mobility limitations 828 (40.89%) 4379 (31.77%) 5207 (32.94%)
 Lower body mobility limitations 1377 (68.00%) 7723 (56.03%) 9100 (57.57%)
 Limitations in ADLsa 93 (4.59%) 494 (3.58%) 587 (3.71%) 
 Limitations in IADLs 373 (18.42%) 1830 (13.28%) 2203 (13.94%)
Geriatric syndromes
 Low cognitive functioninga 675 (33.33%) 4287 (31.10%) 4961 (31.38%)
 Depressive symptomsb 313 (15.46%) 1994 (14.47%) 2307 (14.59%) 
 Incontinence 663 (32.74%) 2862 (20.76%) 3525 (22.30%)
 Severe pain 174 (8.59%) 879 (6.38%) 1053 (6.66%) 
 Visual impairmentd 485 (23.95%) 3105 (22.53%) 3590 (22.71%)
 Hearing Impairment 498 (24.59%) 2558 (18.56%) 3056 (19.33%)
Total 2025 (100.00%) 13,783 (100.00%) 15,808 (100.00%)
Unless indicated otherwise, (unadjusted) comparisons significant at P<0.001.
ADLs, activity of daily living; IADL independent activities of daily living.
a0.05≤P<0.01
bP>0.05.
Warner et al.
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Fig. 1. Results from the multivariable analysis showing the 
association between cancer survivor status and health outcomes, after 
adjustment for sociodemographic characteristics and multimorbidity.
Table 3. Multimorbidity and health outcomes
Variables of interest Cancer survivors Cancer-free individuals Total
Multimorbidity/composite measure
 MM0 148 (7.31%) 1781 (12.92%) 1929 (12.20%)
 MM1 482 (23.81%) 4196 (30.44%) 4678 (29.59%)
 MM2 706 (34.86%) 4344 (31.52%) 5050 (31.95%)
 MM3 689 (34.02%) 3462 (25.12%) 4151 (26.26%)
Self-reported health statusa
 Good/very good/excellent health 1220 (65.21%) 9927 (74.45%) 11,147 (73.31%)
 Fair/poor health 651 (34.79%) 3407 (25.55%) 4058 (26.69%)
Two-year self-reported worse healtha
 No 1322 (70.66%) 10,478 (78.58%) 11,800 (77.61%)
 Yes 549 (29.34%) 2856 (21.42%) 3405 (22.39%)
Two-year mortality
 No 1871 (92.40%) 13,334 (96.74%) 15,205 (96.19%) 
 Yes 154 (7.60%) 449 (3.26%) 603 (3.81%)
Total 2025 (100.00%) 13,783 (100.00%) 15,808 (100.00)
All comparisons significant at P<0.001.
MM0, absence of chronic conditions, functional limitations, or geriatric syndromes; MM1 presence (but without the co-occurrence) of chronic 
conditions, functional limitations, or geriatric syndromes; MM2, co-occurrence of conditions across two of the domains of chronic conditions, 
functional limitations, and geriatric syndromes; MM3, co-occurrence of chronic conditions, functional limitations, and geriatric syndromes. 
aReports limited to respondents alive and interviewed in 2012.
Discussion
Consistent with previous studies [4], we documented a ‘com-
plex health profile’ and a greater multimorbidity burden among 
cancer survivors compared with their cancer-free counterparts. 
With the exception of limitations in activities of daily living, 
depressive symptoms, and visual impairment, we observed 
a higher percentage of various conditions among cancer 
survivors. However, cancer survivors were significantly older, 
and a greater percentage of them were white non-Hispanic 
– perhaps a reflection, downstream, of well-documented dis-
parities in cancer survival experienced by patients of minority 
descent.
Even after adjustment for age, other sociodemographic 
variables, and multimorbidity, cancer survivors were likelier 
to report fair/poor health and 2-year worse health, or to have 
died within 2 years. For health status, it is critically important 
to determine whether self-reported fair/poor health is perceived 
because of their past challenges or whether it reflects unmeas-
ured conditions, such as fatigue. Here, the complex and some-
what paradoxical findings from Fig. 2 deserve some discussion. 
On one hand, with greater time elapsed since cancer diagnosis, 
older cancer survivors become more similar to cancer-free indi-
viduals in their reports of fair/poor health, possibly reflecting the 
‘suppression’ of their cancer experience, as they face the emer-
gence of aging-related physical, functional, psychological, and 
emotional challenges [24]. On the other hand, the fact that can-
cer survivors are likelier to rate their health as having become 
Multimorbidity and health outcomes in older adults
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worse in the previous 2 years regardless of the amount of time 
since diagnosis, even as elevated levels of poor/fair health and 
mortality seem to recede, suggests that cancer survivorship fun-
damentally alters their perceptions of their current health rela-
tive to the past. This phenomenon, described by Kahana et al. 
[25] as posttraumatic transformations, reflects cancer survivors’ 
view that cancer is a “continuing and worrisome experience.” 
For the most part, our findings are consistent with those of 
previous studies, indicating poorer health and greater functional 
impairment in cancer survivors. While we note that our study 
population excludes cancer survivors in whom with cancer had 
been diagnosed within the last 2 years, the lack of association 
between depressive symptoms and cancer survivor status in our 
study differs from prior studies. These studies show that cancer 
survivors continue to perceive cancer’s threats to their quality 
of life, even as they age into older adulthood [26].
Our study findings have important clinical implications. 
First, given cancer survivors’ complex multimorbidity profile, 
the role of primary care physicians (PCPs) in coordinating care 
among the various medical specialists is a critical one, given 
their responsibility to incorporate treatment summaries and sur-
veillance regimens from their survivorship care plan [27]. While 
some prior studies have shown that PCPs can safely manage 
follow-up care in certain patient populations (e.g., early-stage 
breast cancer survivors), others have expressed preference for 
a survivorship care co-managed by PCPs and oncologists [28].
Second, given their poor mental and physical health out-
comes, cancer survivors may benefit from cognitive behavio-
ral therapy and physical activity interventions to improve their 
functioning and health self-assessments. Such programs have 
proven highly effective [15, 29].
Third, it is important that survivorship care plans be tai-
lored to individuals’ physical and mental health, as well as 
psychosocial needs and preferences, and enhance their self-
efficacy [30]. As noted by Halpern and Argenbright [30], 
survivorship programs should be evaluated on their long-term 
outcomes, including quality-adjusted life years and functional 
status; receipt of social support, as well as nutritional and 
rehabilitative services; and as judicious use of health services 
(i.e., avoidance of inappropriate use of resources). 
Finally, given the increase in the number of cancer survivors 
and their improved life expectancy, it is critically important to 
determine whether self-assessed poor and worsening health 
reflects their past challenges or whether it signals unmeasured 
health conditions, such as fatigue. Remedial measures can be 
taken accordingly to improve their health status. As noted by 
Kahana et al. [25], “therapeutic exchanges” based on commu-
nications between patients, health care providers, and mental 
health professionals about patients’ appraisal of their illness, 
the life-changing nature of receiving a diagnosis of and being 
treated for cancer, and stigma can be highly beneficial to the 
patient.
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Fig. 2. Results from the multivariable analysis showing the association between time elapsed since cancer diagnosis and health outcomes, after 
adjustment for sociodemographic characteristics and multimorbidity.
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We note several limitations to our study. First, our study does 
not account for the anatomic site of primary cancer, multiple pri-
mary cancers, recurrences, or cancer stage at diagnosis for the 
first or subsequent cancers, and while cancer survivorship was 
based on self-report, specificity, high negative predictive value, 
and general concordance between self-reported cancer and 
registry-confirmed diagnosis has been shown previously [31]. 
Second, a number of pertinent measures were not available in 
the HRS, including cancer treatment regimen, as well as fatigue, 
which may have helped with the interpretation of these findings. 
Regardless, consistent with a previous study in which we identi-
fied combinations of conditions that are closely associated with 
fair/poor health status and 2-year self-rated worse health [32], 
although basic prevalence measures are included in our models, 
the greater severity of functional limitations and pain experi-
enced among cancer survivors may well explain poor(er) health 
outcomes in this group. With regard to the higher likelihood to 
die within 2 years up until 10 years or more after diagnosis, even 
after adjustment for age and multimorbidity, we note the lack of 
data on cancer recurrence or long-term complications of cancer 
treatment compromising survival.
These limitations notwithstanding, our study has a number 
of strengths. To our knowledge, this is the first study to use the 
HRS and take advantage of the richness of its data to character-
ize cancer survivors’ complex multimorbidity profile based on 
an expansive definition, incorporating not only co-occurring 
chronic conditions but also functional limitations and geriatric 
conditions. This approach is all the more important consider-
ing the expected increase in the number of cancer survivors, 
and their representation in older age groups. This study moves 
beyond traditional conceptualization and measurement of mul-
timorbidity as only a list of diagnoses to included measures of 
functional health morbidity. This more fully reflects the com-
plexity of multimorbidity and its effects on people’s lives.
Conclusion
Cancer survivors are likelier to experience complex multi-
morbidity and, although they eventually have risks of death 
similar to those without a history of cancer, cancer survivors 
continue to rate their health as fair/poor and worsening even a 
decade after diagnosis. These findings indicate the compelling 
need for continued integrated and personalized care for cancer 
survivors. While care should be focused on both the physical 
and the psychological needs in the near term, cancer survivors 
would greatly benefit from continued cognitive behavioral 
interventions to address persisting cancer-related stress.
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